RxDoctor Payments Data

Philip Storey, MD

Ophthalmology · Austin, TXNPI 1053614453

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 37.5% of the total. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$161,308in general payments, 2019–2025

Across 200 payments — averaging $806.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$60K
  • Genentech USA, Inc.$53K
  • Baxter Healthcare$24K
  • Apellis Pharmaceuticals, Inc.$7K
  • Genentech, Inc.$4K
  • Ocular Therapeutix, Inc.$4K
  • plus $8K from 16 others
$1,961,307in research payments, 2019–2025

Across 503 payments — averaging $3899.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$1.1M
  • Eyepoint US, Inc.$812K
  • AbbVie$13K
  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$58,53036%
  • Speaking & faculty fees$82,15651%
  • Travel & lodging$12,5728%
  • Food & beverage$7,8745%
  • Gifts$1760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,308 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$5,189,244
Medicare patients
1,075
Services billed
34,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate81$3,243
Ketorolac Tromethamine70$2,232
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha130$1,399
Atropine Sulfate20$636
Timolol Maleate44$397
Brimonidine Tartrate25$394
Dorzolamide Hcl25$310
Latanoprost17$160

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →